I03-Macromolecular Crystallography
|
Aurelia
Stangl
,
Paul R.
Elliott
,
Adan
Pinto-Fernandez
,
Sarah
Bonham
,
Luke
Harrison
,
Annalisa
Schaub
,
Kerstin
Kutzner
,
Kirstin
Keusekotten
,
Paul T.
Pfluger
,
Farid
El Oualid
,
Benedikt M.
Kessler
,
David
Komander
,
Daniel
Krappmann
Open Access
Abstract: OTULIN (OTU Deubiquitinase With Linear Linkage Specificity) specifically hydrolyzes methionine1 (Met1)-linked ubiquitin chains conjugated by LUBAC (linear ubiquitin chain assembly complex). Here we report on the mass spectrometric identification of the OTULIN interactor SNX27 (sorting nexin 27), an adaptor of the endosomal retromer complex responsible for protein recycling to the cell surface. The C-terminal PDZ-binding motif (PDZbm) in OTULIN associates with the cargo-binding site in the PDZ domain of SNX27. By solving the structure of the OTU domain in complex with the PDZ domain, we demonstrate that a second interface contributes to the selective, high affinity interaction of OTULIN and SNX27. SNX27 does not affect OTULIN catalytic activity, OTULIN-LUBAC binding or Met1-linked ubiquitin chain homeostasis. However, via association, OTULIN antagonizes SNX27-dependent cargo loading, binding of SNX27 to the VPS26A-retromer subunit and endosome-to-plasma membrane trafficking. Thus, we define an additional, non-catalytic function of OTULIN in the regulation of SNX27-retromer assembly and recycling to the cell surface.
|
Sep 2019
|
|
I03-Macromolecular Crystallography
|
Melissa
D'Ascenzio
,
Kathryn M.
Pugh
,
Rebecca
Konietzny
,
Georgina
Berridge
,
Cynthia
Tallant
,
Shaima
Hashem
,
Octovia
Monteiro
,
Jason R.
Thomas
,
Markus
Schirle
,
Stefan
Knapp
,
Brian
Marsden
,
Oleg
Fedorov
,
Chas
Bountra
,
Benedikt M.
Kessler
,
Paul E.
Brennan
Diamond Proposal Number(s):
[10619]
Open Access
Abstract: Bromodomain‐containing proteins are epigenetic modulators involved in a wide range of cellular processes, from recruitment of transcription factors to pathological disruption of gene regulation and cancer development. Since the druggability of these acetyl‐lysine reader domains was established, efforts were made to develop potent and selective inhibitors across the entire family. Here we report the development of a small molecule‐based approach to covalently modify recombinant and endogenous bromodomain‐containing proteins by targeting a conserved lysine and a tyrosine residue in the variable ZA or BC loops. Moreover, the addition of a reporter tag allowed in‐gel visualization and pull‐down of the desired bromodomains.
|
Jan 2019
|
|
I04-Macromolecular Crystallography
|
Saleta
Vazquez-Rodriguez
,
Miranda
Wright
,
Catherine M.
Rogers
,
Adam P.
Cribbs
,
Srikannathasan
Velupillai
,
Martin
Philpott
,
Henry
Lee
,
James E.
Dunford
,
Kilian V. M.
Huber
,
Matthew B.
Robers
,
James D.
Vasta
,
Marie-Laetitia
Thezenas
,
Sarah
Bonham
,
Benedikt
Kessler
,
James
Bennett
,
Oleg
Fedorov
,
Florence
Raynaud
,
Adam
Donovan
,
Julian
Blagg
,
Vassilios
Bavetsias
,
Udo
Oppermann
,
Chas
Bountra
,
Akane
Kawamura
,
Paul E.
Brennan
Diamond Proposal Number(s):
[15433]
Open Access
Abstract: Histone lysine demethylases (KDMs) are involved in the dynamic regulation of gene expression and they play a critical role in several biological processes. Achieving selectivity over the different KDMs has been a major challenge for KDM inhibitor development. Here we report potent and selective KDM5 covalent inhibitors designed to target cysteine residues only present in the KDM5 sub‐family. The covalent binding to the targeted proteins was confirmed by MS and time‐dependent inhibition. Additional competition assays show that compounds were non 2‐OG competitive. Target engagement and ChIP‐seq analysis showed that the compounds inhibited the KDM5 members in cells at nano‐ to micromolar levels and induce a global increase of the H3K4me3 mark at transcriptional start sites.
|
Jan 2019
|
|
I04-Macromolecular Crystallography
|
Suzana
Markolovic
,
Qinqin
Zhuang
,
Sarah E.
Wilkins
,
Charlotte D.
Eaton
,
Martine I.
Abboud
,
Maximiliano J.
Katz
,
Helen E.
Mcneil
,
Robert K.
Leśniak
,
Charlotte
Hall
,
Weston B.
Struwe
,
Rebecca
Konietzny
,
Simon
Davis
,
Ming
Yang
,
Wei
Ge
,
Justin L. P.
Benesch
,
Benedikt M.
Kessler
,
Peter J.
Ratcliffe
,
Matthew E.
Cockman
,
Roman
Fischer
,
Pablo
Wappner
,
Rasheduzzaman
Chowdhury
,
Mathew L.
Coleman
,
Christopher J.
Schofield
Abstract: Biochemical, structural and cellular studies reveal Jumonji-C (JmjC) domain-containing 7 (JMJD7) to be a 2-oxoglutarate (2OG)-dependent oxygenase that catalyzes (3S)-lysyl hydroxylation. Crystallographic analyses reveal JMJD7 to be more closely related to the JmjC hydroxylases than to the JmjC demethylases. Biophysical and mutation studies show that JMJD7 has a unique dimerization mode, with interactions between monomers involving both N- and C-terminal regions and disulfide bond formation. A proteomic approach identifies two related members of the translation factor (TRAFAC) family of GTPases, developmentally regulated GTP-binding proteins 1 and 2 (DRG1/2), as activity-dependent JMJD7 interactors. Mass spectrometric analyses demonstrate that JMJD7 catalyzes Fe(ii)- and 2OG-dependent hydroxylation of a highly conserved lysine residue in DRG1/2; amino-acid analyses reveal that JMJD7 catalyzes (3S)-lysyl hydroxylation. The functional assignment of JMJD7 will enable future studies to define the role of DRG hydroxylation in cell growth and disease.
|
Jun 2018
|
|
I02-Macromolecular Crystallography
|
Marion
Schuller
,
Kerstin
Riedel
,
Ian
Gibbs-Seymour
,
Kristin
Uth
,
Christian
Sieg
,
André P
Gehring
,
Ivan
Ahel
,
Franz
Bracher
,
Benedikt M.
Kessler
,
Jonathan M.
Elkins
,
Stefan
Knapp
Abstract: Macrodomains are conserved protein interaction modules that can be found in all domains of life as well as in certain viruses. Macrodomains mediate recognition of sequence motifs harbouring adenosine diphosphate ribose (ADPR) modifications, thereby regulating a variety of cellular processes. Due to their role in cancer or viral pathogenesis, macrodomains have emerged as potential therapeutic targets, but the unavailability of small molecule inhibitors has hampered target validation studies so far. Here, we describe an efficient screening strategy for identification of small molecule inhibitors that displace ADPR from macrodomains. We report the discovery and characterisation of a macrodomain inhibitor, GeA-69, selectively targeting macrodomain 2 (MD2) of PARP14 with low micromolar affinity. Co-crystallisation of a GeA-69 analogue with PARP14 MD2 revealed an allosteric binding mechanism explaining its selectivity over other human macrodomains. We show that GeA-69 engages PARP14 MD2 in intact cells and prevents its localisation to sites of DNA damage.
|
Oct 2017
|
|
I03-Macromolecular Crystallography
I04-Macromolecular Crystallography
|
Andrew
Turnbull
,
Stephanos
Ioannidis
,
Wojciech W.
Krajewski
,
Adan
Pinto-Fernandez
,
Claire
Heride
,
Agnes C. L.
Martin
,
Louise M.
Tonkin
,
Elizabeth C.
Townsend
,
Shane M.
Buker
,
David R.
Lancia
,
Justin A.
Caravella
,
Angela V.
Toms
,
Thomas M.
Charlton
,
Johanna
Lahdenranta
,
Erik
Wilker
,
Bruce C.
Follows
,
Nicola J.
Evans
,
Lucy
Stead
,
Cristina
Alli
,
Vladislav V.
Zarayskiy
,
Adam C.
Talbot
,
Alexandre J.
Buckmelter
,
Minghua
Wang
,
Crystal L.
Mckinnon
,
Fabienne
Saab
,
Joanna F.
Mcgouran
,
Hannah
Century
,
Malte
Gersch
,
Marc S.
Pittman
,
C. Gary
Marshall
,
Tony M.
Raynham
,
Mary
Simcox
,
Lorna M. D.
Stewart
,
Sheila B.
Mcloughlin
,
Jaime A.
Escobedo
,
Kenneth W.
Bair
,
Christopher J.
Dinsmore
,
Tim R.
Hammonds
,
Sunkyu
Kim
,
Sylvie
Urbé
,
Michael J.
Clague
,
Benedikt M.
Kessler
,
David
Komander
Diamond Proposal Number(s):
[15419, 5070]
Abstract: Ubiquitination controls the stability of most cellular proteins, and its deregulation contributes to human diseases including cancer. Deubiquitinases remove ubiquitin from proteins, and their inhibition can induce the degradation of selected proteins, potentially including otherwise ‘undruggable’ targets. For example, the inhibition of ubiquitin-specific protease 7 (USP7) results in the degradation of the oncogenic E3 ligase MDM2, and leads to re-activation of the tumour suppressor p53 in various cancers. Here we report that two compounds, FT671 and FT827, inhibit USP7 with high affinity and specificity in vitro and within human cells. Co-crystal structures reveal that both compounds target a dynamic pocket near the catalytic centre of the auto-inhibited apo form of USP7, which differs from other USP deubiquitinases. Consistent with USP7 target engagement in cells, FT671 destabilizes USP7 substrates including MDM2, increases levels of p53, and results in the transcription of p53 target genes, induction of the tumour suppressor p21, and inhibition of tumour growth in mice.
|
Oct 2017
|
|
I04-1-Macromolecular Crystallography (fixed wavelength)
|
Diamond Proposal Number(s):
[15916]
Open Access
Abstract: The methionine 1 (M1)-specific deubiquitinase (DUB) OTULIN acts as a negative regulator of nuclear factor κB signaling and immune homeostasis. By replacing Gly76 in distal ubiquitin (Ub) by dehydroalanine we designed the diubiquitin (diUb) activity-based probe UbG76Dha-Ub (OTULIN activity-based probe [ABP]) that couples to the catalytic site of OTULIN and thereby captures OTULIN in its active conformation. The OTULIN ABP displays high selectivity for OTULIN and does not label other M1-cleaving DUBs, including CYLD. The only detectable cross-reactivities were the labeling of USP5 (Isopeptidase T) and an ATP-dependent assembly of polyOTULIN ABP chains via Ub-activating E1 enzymes. Both cross-reactivities were abolished by the removal of the C-terminal Gly in the ABP's proximal Ub, yielding the specific OTULIN probe UbG76Dha-UbΔG76 (OTULIN ABPΔG76). Pull-downs demonstrate that substrate-bound OTULIN associates with the linear ubiquitin chain assembly complex (LUBAC). Thus, we present a highly selective ABP for OTULIN that will facilitate studying the cellular function of this essential DUB.
|
Sep 2017
|
|
I02-Macromolecular Crystallography
|
Paul R.
Elliott
,
Derek
Leske
,
Matous
Hrdinka
,
Katrin
Bagola
,
Berthe k.
Fiil
,
Stephen h.
Mclaughlin
,
Jane
Wagstaff
,
Norbert
Volkmar
,
John C.
Christianson
,
Benedikt M.
Kessler
,
Stefan M. V.
Freund
,
David
Komander
,
Mads
Gyrd-Hansen
Diamond Proposal Number(s):
[11235]
Open Access
Abstract: The linear ubiquitin chain assembly complex (LUBAC) regulates immune signaling, and its function is regulated by the deubiquitinases OTULIN and CYLD, which associate with the catalytic subunit HOIP. However, the mechanism through which CYLD interacts with HOIP is unclear. We here show that CYLD interacts with HOIP via spermatogenesis-associated protein 2 (SPATA2). SPATA2 interacts with CYLD through its non-canonical PUB domain, which binds the catalytic CYLD USP domain in a CYLD B-box-dependent manner. Significantly, SPATA2 binding activates CYLD-mediated hydrolysis of ubiquitin chains. SPATA2 also harbors a conserved PUB-interacting motif that selectively docks into the HOIP PUB domain. In cells, SPATA2 is recruited to the TNF receptor 1 signaling complex and is required for CYLD recruitment. Loss of SPATA2 increases ubiquitination of LUBAC substrates and results in enhanced NOD2 signaling. Our data reveal SPATA2 as a high-affinity binding partner of CYLD and HOIP, and a regulatory component of LUBAC-mediated NF-κB signaling.
|
Sep 2016
|
|
I03-Macromolecular Crystallography
|
Sebastian
Mathea
,
Kamal R.
Abdul Azeez
,
Eidarus
Salah
,
Cynthia
Tallant
,
Finn
Wolfreys
,
Rebecca
Konietzny
,
Roman
Fischer
,
Hua Jane
Lou
,
Paul E.
Brennan
,
Gisela
Schnapp
,
Alexander
Pautsch
,
Benedikt M.
Kessler
,
Benjamin E.
Turk
,
Stefan
Knapp
Abstract: The mixed lineage kinase ZAK is a key regulator of the MAPK pathway mediating cell survival and inflammatory response. ZAK is targeted by several clinically approved kinase inhibitors, and inhibition of ZAK has been reported to protect from doxorubicin-induced cardiomyopathy. On the other hand, unintended targeting of ZAK has been linked to severe adverse effects such as the development of cutaneous squamous cell carcinoma. Therefore, both specific inhibitors of ZAK, as well as anticancer drugs lacking off-target activity against ZAK, may provide therapeutic benefit. Here, we report the first crystal structure of ZAK in complex with the B-RAF inhibitor vemurafenib. The cocrystal structure displayed a number of ZAK-specific features including a highly distorted P loop conformation enabling rational inhibitor design. Positional scanning peptide library analysis revealed a unique substrate specificity of the ZAK kinase including unprecedented preferences for histidine residues at positions −1 and +2 relative to the phosphoacceptor site. In addition, we screened a library of clinical kinase inhibitors identifying several inhibitors that potently inhibit ZAK, demonstrating that this kinase is commonly mistargeted by currently used anticancer drugs.
|
Mar 2016
|
|
I04-1-Macromolecular Crystallography (fixed wavelength)
|
Mikael
Altun
,
Thomas
Walter
,
Holger B.
Kramer
,
P
Herr
,
Alexander
Iphöfer
,
Johan
Boström
,
Yael
David
,
Alia
Komsany
,
Nicola
Ternette
,
Ami
Navon
,
David I.
Stuart
,
Jingshan
Ren
,
Benedikt M.
Kessler
Diamond Proposal Number(s):
[10627]
Open Access
Abstract: Ovarian tumor domain containing proteases cleave ubiquitin (Ub) and ubiquitin-like poly- peptides from proteins. Here we report the crystal structure of human otubain 2 (OTUB2) in complex with a ubiquitin-based covalent inhibitor, Ub-Br2. The ubiquitin binding mode is ori- ented differently to how viral otubains (vOTUs) bind ubiquitin/ISG15, and more similar to yeast and mammalian OTUs. In contrast to OTUB1 which has exclusive specificity towards Lys48 poly-ubiquitin chains, OTUB2 cleaves different poly-Ub linked chains. N-terminal tail swapping experiments between OTUB1 and OTUB2 revealed how the N-terminal structural motifs in OTUB1 contribute to modulating enzyme activity and Ub-chain selectivity, a trait not observed in OTUB2, supporting the notion that OTUB2 may affect a different spectrum of substrates in Ub-dependent pathways.
|
Jan 2015
|
|
